Melanoma-restricted genes

Journal of Translational Medicine

Volumn 2, Issue , 2004, Pages

  Wang, Ena ^a   Panelli, Monica C ^a   Zavaglia, Katia ^a   Mandruzzato, Susanna ^b   Hu, Nan ^c   Taylor, Phil R ^c   Seliger, Barbara ^d   Zanovello, Paolo ^b   Freedman, Ralph S ^e   Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTEGRIN; AMYLOID PRECURSOR PROTEIN; ASIALOGLYCOPROTEIN RECEPTOR; BETA7 INTEGRIN; BRUTON TYROSINE KINASE; CD27 ANTIGEN; CD37 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR; ENOLASE; FC RECEPTOR; GRANZYME A; INTERLEUKIN 11 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21 RECEPTOR; LYMPHOCYTE ANTIGEN; MYOSIN; NATURAL KILLER CELL RECEPTOR NKG2D; PHOSPHOPROTEIN PHOSPHATASE; PROCOLLAGEN LYSINE 2 OXOGLUTARATE 5 DIOXYGENASE; PROSTACYCLIN RECEPTOR; PROTEIN BNIP3; SOMATOMEDIN BINDING PROTEIN; SYNDECAN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ARTICLE; CLINICAL STUDY; DRUG TARGETING; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; HIGH THROUGHPUT SCREENING; HOST CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; KIDNEY CARCINOMA; MELANOMA; METASTASIS;

EID: 16844376724     PISSN: 14795876     EISSN: None     Source Type: Journal    
DOI: 10.1186/1479-5876-2-34     Document Type: Article

References (56)

1. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1998, 17:2105-2116.
2. Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Fink KI, Rubinstein L, Louie A, Mier JW, Gucalp R: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993, 11:661-670.
3. Wang E, Marincola FM: cDNA microarrays and the enigma of melanoma immune responsiveness. Cancer J Sci Am 2001, 7: 6-23.
4. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA: Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol 1992, 148:638-643.
5. Kawakami Y, Rosenberg SA: T-cell recognition of self peptides as tumor rejection antigens. Immunol Res 1996, 15: 79-190.
6. Kawakami Y: Identification of human tumor antigens recognized by T-cells and their use for immunotherapy. Int J Hematol 2003, 77:427-434.
7. Paschen A, Eichmuller S, Schadendorf D: Identification of tumor antigens and T-cell epitopes, and its clinical application. Cancer Immunol Immunother 2004, 53:196-203.
8. Yang JC, Topalian SL, Parkinson D, Schwartzentruber DJ, Weber JS, Ettinghausen SE, White DE, Steinberg SM, Cole DJ, Kim HI: A randomized comparison of high dose and low dose intravenous interleukin-2 for the treatment of metastatic renal cell carcinoma. J Clin Oncol 1994, 12:1572-6.
9. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S: Tumors as elusive targets of T cell-directed immunotherapy. Trends Immunol 2003, 24:334-341.
10. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, Alexander HR, Duray PH, Herlyn M, Restifo NP, Liu ET, Rosenberg SA, Marincola FM: Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002, 62:3581-3586.
11. Wang E, Lichtenfels R, Bukur J, Ngalame Y, Panelli MC, Seliger B, Marincola FM: Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. Cancer Res 2004 in press.
12. Takashi M, Sakata T, Inaguma Y, Kato K: Elevated concentrations of gamma-enolase in renal cell tumors in rats: similarity to renal cell carcinoma in man. Urol Res 1996, 24:375-379.
13. Yaman O, Baltaci S, Arikan N, Ozdiler E, Gogus O, Muftuoglu YZ: Serum neuron specific enolase: can it be a tumour marker for renal cell carcinoma? Int Urol Nephrol 1996, 28:207-210.
14. Gopalkrishnan RV, Sauane M, Fisher PB: Cytokine and tumor cell apoptosis inducing activity of mda-7/IL-24. Int Immunopharmacol 2004, 4:635-647.
15. Quast T, Wehner S, Kirfel G, Jaeger K, De Luca M, Herzog V: sAPP as a regulator of dendrite motility and melanin release in epidermal melanocytes and melanoma cells. FASEB J 2003, 17: 739-1741.
16. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001, 19:3477-3482.
17. Powell DJ Jr, Rosenberg SA: Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J Immunother 2004, 27:36-47.
18. Weeraratna AT, Becker D, Carr KM, Duray PH, Rosenblatt KP, Yang S, Chen Y, Bittner M, Strausberg RL, Riggins GJ, Wagner U, Kallioniemi OP, Trent JM, Morin PJ, Meltzer PS: Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene 2004, 23:2264-2274.
19. Boon K, Edwards JB, Siu IM, Olschner D, Eberhart CG, Marra MA, Strausberg RL, Riggins GJ: Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene 2003, 22:7687-7694.
20. Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M: The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 2004, 10:4307-4313.
21. Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA: Analysis of expression of the melanoma associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother 1996, 19:192-205.
22. Cormier JN, Panelli MC, Hackett JA, Bettinotti MP, Mixon A, Wunderlich J, Parker LL, Restifo NP, Ferrone S, Marincola FM: Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer 1999, 80:781-790.
23. Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Steinberg SM, Rosenberg SA, Marincola FM: Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998, 75:517-524.
24. Cormier JN, Abati A, Fetsch P, Hijazi YM, Rosenberg SA, Marincola FM, Topalian SL: Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J Immunother 1998, 21:27-31.
25. Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch P, Riker AI, Kammula US, Rosenberg SA, Marincola FM: Short term kinetics of tumor antigen expression in response to vaccination. J Immunol 2001, 167:1809-1820.
26. Matsumoto K, Nakamura T: NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 2003, 94:321-327.
27. Panelli MC, Wang E, Phan G, Puhlmann M, Miller L, Ohnmacht GA, Klein HG, Marincola FM: Genetic profiling of peripharal mononuclear cells and melanoma metastases in response to systemic interleukin-2 administration. Genome Biol 2002, 3: ESEARCH0035.
28. Monsurro' V, Wang E, Panelli MC, Nagorsen D, Jin P, Katia Z, Smith K, Ngalame Y, Even J, Marincola FM: Active-specific immunization against cancer: is the problem at the receiving end? Sem Cancer Biol 2003, 13:473-480.
29. Monsurro VV, Wang E, Yamano Y, Migueles SA, Panelli MC, Smith K, Nagorsen D, Connors M, Jacobson S, Marincola FM: Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 2004, 104:1970-1978.
30. Zheng T, Zhu Z, Wang Z, Homer RJ, Ma B, Riese RJ Jr, Chapman HA Jr, Shapiro SD, Elias JA: Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest 2000, 106:1081-1093.
31. Croft M: Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev 2003, 14:265-273.
32. Robertson MJ: Role of chemokines in the biology of natural killer cells. J Leukoc Biol 2002, 71:173-183.
33. Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T: Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004, 24:34-40.
34. Collins M, Whitters MJ, Young DA: IL-21 and IL-21 receptor: a new cytokine pathway modulates innate and adaptive immunity. Immunol Res 2003, 28:131-140.
35. Parrish-Novak J, Foster DC, Holly RD, Clegg CH: Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 2002, 72:856-863.
36. Zhang L, Pagano JS: Structure and function of IRF-7. J Interferon Cytokine Res 2002, 22:95-101.
37. Hiscott J, Grandvaux N, Sharma S, Tenoever BR, Servant MJ, Lin R: Convergence of the NF-kappaB and interferon signaling pathways in the regulation of antiviral defense and apoptosis. Ann N Y Acad Sci 2003, 1010:237-248.
38. Levy DE, Marie I, Smith E, Prakash A: Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback. J Interferon Cytokine Res 2002, 22:87-93.
39. Conti P, Kempuraj D, Kandere K, Di Gioacchino M, Reale M, Barbacane RC, Castellani ML, Mortari U, Boucher W, Letourneau R, Theoharides TC: Interleukin-16 network in inflammation and allergy. Allergy Asthma Proc 2002, 23:103-108.
40. Okubo Y, Tsukadaira A, Takashi S, Kubo K, Koyama S: Chemotaxis of human CD4+ eosinophils. Int Arch Allergy Immunol 2001, 125(Suppl 1):19-21.
41. Eichmuller S, Usener D, Jochim A, Schadendorf D: mRNA expression of tumor-associated antigens in melanoma tissues and cell lines. Exp Dermatol 2002, 11:292-301.
42. Harpio R, Einarsson R: S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 2004, 37:512-518.
43. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R: B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23:6292-6298.
44. Steingrimsson E, Copeland NG, Jenkins NA: Melanocytes and the Microphthalmia Transcription Factor Network. Annu Rev Genet 2004.
45. Kontochristopoulos GJ, Stavropoulos PG, Krasagakis K, Goerdt S, Zouboulis CC: Differentiation between merkel cell carcinoma and malignant melanoma: An immunohistochemical study. Dermatology 2000, 201:123-126.
46. Ramos-Vara JA, Beissenherz ME, Miller MA, Johnson GC, Pace LW, Fard A, Kottler SJ: Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Vet Pathol 2000, 37:597-608.
47. Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J: High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 1999, 264:751-758.
48. Rumpler G, Becker B, Hafner C, McClelland M, Stolz W, Landthaler M, Schmitt R, Bosserhoff A, Vogt T: Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes. Exp Dermatol 2003, 12:761-771.
49. Repp AC, Mayhew ES, Apte S, Niederkorn JY: Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol 2000, 165:710-715.
50. Nyormoi O, Bar-Eli M: Transcriptional regulation of metastasis- related genes in human melanoma. Clin Exp Metastasis 2003, 20:251-263.
51. Wang E, Miller L, Ohnmacht GA, Liu E, Marincola FM: High fidelity mRNA amplification for gene profiling using cDNA microarrays. Nature Biotech 2000, 17:457-459.
52. Wang E, Marincola FM: Amplification of small quantities of mRNA for transcript analysis. In DNA arrays - A Molecular Cloning Manual Edited by: Bowtell D, Sambrook J. Cold Springs Harbor, NY: Cold Spring Harbor Laboratory Press; 2002: 204-213.
53. Feldman AL, Costouros NG, Wang E, Qian M, Marincola FM, Alexander HR, Libutti SK: Advantages of mRNA amplification for microarray analysis. Biotechniques 2002, 33:906-914.
54. Jin P, Zhao Y, Ngalame Y, Panelli MC, Nagorsen D, Monsurro V, Smith K, Hu N, Su H, Taylor PR, Marincola FM, Wang E: Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics. 2004, 13:55.
55. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998, 95:14863-14868.
56. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO: Systematic variation in gene expression patterns in human cancer cell lines. Nature Genetics 2000, 24:227-235.